Skip to main content
Equasens logo

Equasens — Investor Relations & Filings

Ticker · EQS ISIN · FR0012882389 LEI · 96950066I7XVFGZI8L92 PA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2022-09-30 Report Publication Anno…
Country FR France
Listing PA EQS

About Equasens

https://equasens.com

Equasens is a company specializing in healthcare IT solutions for professionals and establishments. It develops and provides a range of products including professional software, electronic equipment, connected devices, and digital health solutions. The company's offerings cater to a diverse client base, including pharmacies, hospitals, nursing homes (EHPADs), home care services, and independent medical practitioners. The primary objective of its solutions is to improve the quality of patient care by facilitating the secure sharing of health data, enhancing communication between different care providers, and optimizing the coordination of care pathways across outpatient, hospital, and home care settings.

Recent filings

Filing Released Lang Actions
EQUASENS : Modalités de mise à disposition du rapport financier semestriel 2022
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" and explicitly states: "EQUASENS annonce la publication de son rapport financier semestriel au 30 juin 2022". It further mentions that the report has been filed with the AMF and provides links where the full report can be accessed. Since the document itself is an announcement about the publication of a report (a semi-annual financial report, which aligns with the 'Interim / Quarterly Report' definition, but the document's function is the announcement itself), and given its short length (2386 chars), it fits the criteria for a Report Publication Announcement (RPA) according to Rule #2 (The 'MENU VS MEAL' Rule). If the text provided were the actual comprehensive semi-annual report, it would be classified as 'IR' (Interim / Quarterly Report), but this text is merely the notice of its availability.
2022-09-30 French
EQUASENS : Rapport Financier Semestriel 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Rapport Financier Semestriel 2022' (Half-Year Financial Report 2022) for the period ending June 30, 2022. It contains comprehensive financial statements, including the balance sheet, income statement, and cash flow statement, as well as notes to the accounts. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). H2 2022
2022-09-30 French
EQUASENS: H1 2022 Results
Interim / Quarterly Report Classification · 1% confidence The document is a press release detailing the H1 2022 financial results for the Equasens Group. It includes key financial metrics (Revenue, Operating Income, Net Profit), a breakdown of divisional performance, balance sheet highlights, and management commentary. Since it provides comprehensive financial data for a period shorter than a full fiscal year (six months) and is not merely an announcement of a report's availability, it is classified as an Interim/Quarterly Report. H1 2022
2022-09-22 English
EQUASENS : Résultats Semestriels 2022
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2022 (Semestriels 2022). It contains detailed financial tables (income statement, balance sheet items), analysis of business divisions, management commentary on performance, and outlook. It is not a mere announcement (RPA) as it provides substantive financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report. H1 2022
2022-09-22 French
EQUASENS (ex-PHARMAGEST INTERACTIVE) : Chiffre d’affaires du 1er semestre 2022
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" and focuses entirely on reporting the financial results for the "1er semestre 2022" (First Half 2022), detailing revenue figures, divisional performance, and key operational highlights for the period ending June 30, 2022. It also includes a section announcing the future calendar for the release of the half-year results ("Publication des résultats semestriels"). This structure—a press release summarizing period results—is characteristic of an Earnings Release (ER). Although it covers a half-year period, which might suggest an Interim Report (IR), the format is a concise press release highlighting key figures rather than the comprehensive financial statements typically found in a full IR filing. Furthermore, the document explicitly announces the date for the 'Publication des résultats semestriels' (September 22), which is a common feature of an ER preceding the full IR filing. Given the focus on initial results announcement via a press release, ER is the most appropriate classification. H1 2022
2022-08-03 French
EQUASENS (ex-Pharmagest Interactive): H1 2022 Revenue
Earnings Release Classification · 1% confidence The document is titled 'PRESS RELEASE' and reports on 'H1 2022 Revenue' and 'H1 2022 business highlights', providing detailed financial figures for the first six months of the year (€103.57m revenue). It also includes a financial calendar noting the 'Publication of H1 results' on September 22, 2022, and the 'Presentation of H1 results' on September 23, 2022. Since this document itself is the initial announcement of the period's financial performance (H1 2022) and is presented as a press release summarizing key figures, it fits the definition of an Earnings Release (ER). It is not the comprehensive 'Interim Report' (IR) itself, but the preliminary announcement of results. H1 2022
2022-08-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.